FrancophonIA/ELRC3.0 huggingface dataset:
English: In neonates one week of age, lamivudine oral clearance was reduced when compared to paediatric patients and is likely to be due to immature renal function and variable absorption.
Slovenian: Pri novorojenčkih, starih en teden, je bil peroralni očistek lamivudina manjši v primerjavi s pediatričnimi bolniki, kar pripisujejo nerazvitemu delovanju ledvic in spremenljivi absorpciji.
English: People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections).
Slovenian: Boniki z napredovalo okužbo s HIV (AIDS-om) imajo oslabel imunski sistem, zato je pri njih večja verjetnost, za nastanek resnih okužb (oportunističnih okužb).
English: At the highest dosage levels, minor effects on indicators of liver and kidney function were seen together with occasional reductions in liver weight.
Slovenian: Pri največjih odmerkih so opazili manjše učinke na pokazatelje delovanja jeter in ledvic ter občasno zmanjšanje teže jeter.
English: Multiple drug antiretroviral therapy containing lamivudine has been shown to be effective in antiretrovirally-naive patients as well as in patients presenting with viruses containing the M184V mutations.
Slovenian: Protiretrovirusno zdravljenje z več zdravili, ki vključuje lamivudin, se je izkazalo za učinkovito pri bolnikih, ki se še niso zdravili s protiretrovirusnimi zdravili, in pri bolnikih, okuženih z virusi, ki vsebujejo mutacije M184V.
English: Dosing recommendations - Adults, adolescents and children (weighing at least 25 kg):
Slovenian: Priporočila za odmerjanje - Odrasli, mladostniki in otroci (ki tehtajo vsaj 25 kg):
English: Therefore, maintaining lamivudine therapy despite emergence of M184V mutation should only be considered in cases where no other active NRTI's are available.
Slovenian: Nadaljevanje zdravljenja z lamivudinom kljub mutaciji M184V pride v poštev samo v primerih, ko ni na voljo drugih učinkovitih NRTI.
English: It is metabolised intracellularly to the active moiety, lamivudine 5'-triphosphate.
Slovenian: Znotrajcelično se presnavlja v aktivno obliko, lamivudin 5'-trifosfat.
English: Children receiving lamivudine oral solution concomitantly with other antiretroviral oral solutions in clinical trials developed viral resistance more frequently than children receiving tablets (see the description of the clinical experience in paediatric population (ARROW study) and section 5.2).
Slovenian: Otroci, ki so v kliničnih preskušanjih prejemali peroralno raztopino lamivudina sočasno z drugimi protiretrovirusnimi peroralnimi raztopinami, so pogosteje razvili virusno odpornost kot otroci, ki so prejemali tablete (glejte opis kliničnih izkušenj pri pediatrični populaciji (študija ARROW) in poglavje 5.2).
English: Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.
Slovenian: Pri bolnikih s kroničnim hepatitisom B ali C, ki se zdravijo s kombinacijo protiretrovirusnih zdravil, obstaja večje tveganje za hude in potencialno smrtne neželene učinke, povezane z jetri.
English: Zidovudine has no effect on the pharmacokinetics of lamivudine (see section 5.2).
Slovenian: Zidovudin ni imel učinka na farmakokinetiko lamivudina (glejte poglavje 5.2).
English: -2.3% (95% CI -9.3% to +4.7%), p=0.52
Slovenian: -2,3 % (95-% IZ od -9,3 % do +4,7 %), p = 0,52
English: Remember to tell your doctor or pharmacist if you begin taking a new medicine while you are taking Lamivudine Teva Pharma B.V..
Slovenian: Ne pozabite povedati zdravniku ali farmacevtu, če boste začeli jemati novo zdravilo, medtem ko jemljete zdravilo Lamivudine Teva Pharma B.V.
English: The true extent of penetration or relationship with any clinical efficacy is unknown.
Slovenian: Dejanski obseg vstopanja lamivudina v osrednje živčevje in korelacija s klinično učinkovitostjo nista znana.
English: Clinical end-point data indicate that lamivudine in combination with zidovudine, results in a significant reduction in the risk of disease progression and mortality.
Slovenian: Podatki končne točke ocene klinične učinkovitosti kažejo, da lamivudin v kombinaciji z zidovudinom pomembno zmanjša tveganje za napredovanje bolezni in smrt.
English: • emtricitabine (used to treat HIV infection).
Slovenian: • emtricitabin (uporablja se pri zdravljenju okužb s HIV),
English: Lamivudine was not mutagenic in bacterial tests but, like many nucleoside analogues, showed activity in an in vitro cytogenetic assay and the mouse lymphoma assay.
Slovenian: Lamivudin ni pokazal mutagenosti v poskusih z bakterijami, vendar pa je, kot številni nukleozidni analogi, pokazal aktivnost v citogenetskem testu in vitro in testu na mišjem limfomu.
English: The nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are unlikely to interact with lamivudine.
Slovenian: Nukleozidni analogi (npr. didanozin), kot je zidovudin, se ne izločajo z uporabo tega mehanizma, zato je verjetnost njihovega medsebojnega delovanja z lamivudinom majhna.
English: 5 to <15
Slovenian: 5 do < 15
English: Coadministration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC∞) and 28%, 52%, and 55% in the Cmax of lamivudine in adults.
Slovenian: Sočasna uporaba raztopine sorbitola (3,2 g; 10,2 g ; 13,4 g) z enkratnim odmerkom 300 mg lamivudina v peroralni raztopini je pri odraslih povzročila od količine sorbitola odvisno zmanjšanje izpostavljenosti (AUC∞) lamivudinu za 14 %, 32 % oziroma 36 % ter zmanjšanje Cmax lamivudina za 28 %, 52 % in 55 %.
English: Rare: Rhabdomyolysis.
Slovenian: Redki: rabdomioliza.
English: Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin (<16%-36% to serum albumin in in vitro studies).
Slovenian: Lamivudin kaže v terapevtskem razponu odmerjanja linearno farmakokinetiko in majhno stopnjo vezave na beljakovino albumin v plazmi (študije in vitro so pokazale manj kot 16- do 36-odstotno vezavo na albumin v serumu).
English: The abacavir + lamivudine once daily dosing group was demonstrated to be non-inferior to the twice daily group according to the pre-specified non-inferiority margin of -12%, for the primary endpoint of <80 c/mL at Week 48 as well as at Week 96 (secondary endpoint) and all other thresholds tested (<200 c/mL, <400 c/mL, <1000 c/mL), which all fell well within this non-inferiority margin.
Slovenian: Dokazano je bilo, da je skupina z odmerjanjem abakavirja + lamivudina enkrat na dan neinferiorna skupini z odmerjanjem dvakrat na dan glede na vnaprej opredeljeno mejo neinferiornosti -12 %, za primarni opazovani dogodek < 80 kopij/ml v 48. tednu in v 96. tednu (sekundarni opazovani dogodek) ter vse druge testirane prage (< 200 kopij/ml, < 400 kopij/ml, < 1000 kopij/ml), ki so bili vsi znotraj omenjene meje neinferiornosti.
English: This variant arises both in vitro and in HIV-1 infected patients treated with lamivudine-containing antiretroviral therapy.
Slovenian: Ta različica se pojavi in vitro in pri bolnikih, okuženih z virusom HIV-1, ki se zdravijo s protiretrovirusnimi zdravili, vključno z lamivudinom.
English: Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy, and should be monitored according to standard practice.
Slovenian: Pri bolnikih z obstoječimi motnjami v delovanju jeter, vključno s kroničnim aktivnim hepatitisom, se med kombiniranim protiretrovirusnim zdravljenjem pogosteje pojavljajo nepravilnosti v delovanju jeter, zato je treba te bolnike nadzorovati skladno s standardno prakso.
English: This may be administered as either 150 mg twice daily or 300 mg once daily (see section 4.4).
Slovenian: To se lahko vzame v dveh dnevnih odmerkih po 150 mg ali enkrat dnevno po 300 mg (glejte poglavje 4.4).
English: Glomerular filtration estimates suggests that to achieve similar adult and paediatric exposure, an appropriate dose for children aged six weeks and older could be 8 mg/kg/day.
Slovenian: Ocene glomerulne filtracije nakazujejo, da je primeren odmerek za otroke, stare šest tednov in več, ki omogoča dosego podobne izpostavljenosti kot pri odraslih in pediatričnih bolnikih, lahko 8 mg/kg/dan.
English: The triphosphate has selective inhibitory activity against HIV-1 and HIV-2 replication in vitro, it is also active against zidovudine-resistant clinical isolates of HIV.
Slovenian: Trifosfat deluje kot selektiven zaviralec replikacije virusov HIV-1 in HIV-2 in vitro, učinkuje pa tudi na klinične izolate virusa HIV, ki so odporni na zidovudin.
English: Adults, adolescents and children who weigh at least 25 kg The usual dose is one 300 mg tablet once a day.
Slovenian: Odrasli, mladostniki in otroci, ki tehtajo vsaj 25 kg: Običajni odmerek je ena 300 mg tableta enkrat na dan.
English: Liver disease: If lamivudine is being used concomitantly for the treatment of HIV and HBV, additional information relating to the use of lamivudine in the treatment of hepatitis B infection is available in the lamivudine 100 mg SmPC.
Slovenian: Bolezen jeter: v primeru sočasnega zdravljenja bolezni HIV in hepatitisa B z lamivudinom so dodatne informacije, ki se nanašajo na uporabo lamivudina pri zdravljenju okužbe z virusom hepatitisa B, na voljo v povzetku glavnih značilnosti zdravila za lamivudin 100 mg.
English: Cross-resistance conferred by the M184V RT is limited within the nucleoside inhibitor class of antiretroviral agents.
Slovenian: Navzkrižna odpornost, ki jo prenaša M184V RT, je med protiretrovirusnimi učinkovinami omejena na nukleozidne zaviralce.
English: Uncommon: Neutropenia and anaemia (both occasionally severe), thrombocytopenia.
Slovenian: Občasni: nevtropenija in anemija (obe sta občasno zelo izraziti), trombocitopenija.
English: Administration of lamivudine at very high dose levels in acute animal studies did not result in any organ toxicity.
Slovenian: Dajanje zelo velikih odmerkov lamivudina v študijah akutnega odmerjanja pri živalih ni imelo toksičnega vpliva na noben organ.
English: • other medicines containing lamivudine (used to treat HIV infection or hepatitis B infection).
Slovenian: • druga zdravila, ki vsebujejo lamivudin (uporabljajo se pri zdravljenju okužb s HIV ali okužb s hepatitisom B),
English: Hepatic impairment: Data obtained in patients with moderate to severe hepatic impairment shows that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction.
Slovenian: Okvara jeter: podatki, pridobljeni pri bolnikih z zmerno do hudo okvaro jeter, kažejo, da jetrna disfunkcija nima znatnega vpliva na farmakokinetične lastnosti lamivudina.
English: Summary of Stead-State Plasma Lamivudine AUC (0-24) (µg•h/mL) and Statistical Comparisons for Once and Twice-Daily Oral Administration Across Studies
Slovenian: Povzetek AUC (0-24) lamivudina v plazmi v stanju dinamičnega ravnovesja (µg.h/ml) in statistične primerjave peroralne uporabe enkrat in dvakrat na dan v študijah
English: General disorders and administration site conditions Common: Fatigue, malaise, fever.
Slovenian: Splošne težave in spremembe na mestu aplikacije Pogosti: utrujenost, slabo počutje, vročina.
English: The mean ratio CSF/serum lamivudine concentration 2-4 hours after oral administration was approximately 0.12.
Slovenian: Povprečno razmerje koncentracij lamivudina v cerebrospinalni tekočini in serumu 2 do 4 ure po peroralnem vnosu je približno 0,12.
English: However, unless the patient has renal impairment, no dosage adjustment of lamivudine is necessary (see section 4.2).
Slovenian: Če bolnik nima okvare ledvic, odmerka lamivudina kljub temu ni treba prilagoditi (glejte poglavje 4.2).
English: Read the information ‘Other possible side effects of combination therapy for HIV' in section 4 of this leaflet.
Slovenian: Preberite dodatne informacije v poglavju 4 »Drugi možni neželeni učinki kombiniranega zdravljenja okužbe s HIV« v tem navodilu.
English: Abacavir maintains its antiretroviral activities against lamivudineresistant HIV-1 harbouring only the M184V mutation.
Slovenian: Abakavir ohranja protiretrovirusno delovanje na virus HIV-1, ki je odporen na lamivudin in ima samo mutacijo M184V.
English: Lamivudine at a dose of 100 mg once daily has also been shown to be effective for the treatment of adult patients with chronic HBV infection (for details of clinical studies, see the prescribing information for lamivudine 100 mg).
Slovenian: Ugotovili so, da je lamivudin v odmerku 100 mg enkrat dnevno učinkovit tudi za zdravljenje odraslih bolnikov s kronično okužbo z virusom hepatitisa B (podrobnosti iz kliničnih študij so v povzetku glavnih značilnosti lamivudina 100 mg).
English: A transplacental genotoxicity study conducted in monkeys compared zidovudine alone with the combination of zidovudine and lamivudine at human-equivalent exposures.
Slovenian: V študiji genotoksičnosti prek placente so pri opicah primerjali sam zidovudin s kombinacijo zidovudina in lamivudina v odmerkih, kakršnim so izpostavljeni ljudje.
English: Children weighing ≥20 kg to <25 kg: The recommended dose is 225 mg daily.
Slovenian: Otroci, ki tehtajo ≥ 20 kg in < 25 kg: Priporočeni odmerek je 225 mg dnevno.
English: Immune Reactivation Syndrome: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Slovenian: Sindrom imunske reaktivacije: pri bolnikih, ki so okuženi z virusom HIV in imajo hudo imunsko pomanjkljivost, lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART) nastopi vnetna reakcija na asimptomatske ali rezidualne oportunistične patogene in povzroči resna klinična stanja ali poslabšanje simptomov.
English: Musculoskeletal and connective tissue disorders Common: Arthralgia, muscle disorders.
Slovenian: Bolezni mišično-skeletnega sistema in vezivnega tkiva Pogosti: artralgija, bolezni mišic.
English: At a therapeutic dose of 300 mg once daily, the mean (CV) steady-state Cmax, Cmin and 24h AUC are 2.0 µg/ml (26%), 0.04 µg/ml (34%) and 8.9 µg•h/ml (21%), respectively.
Slovenian: Pri terapevtskem odmerku 300 mg enkrat dnevno so v stanju dinamičnega ravnovesja povprečne (KV) vrednosti Cmax, Cmin in 24-urna vrednost AUC 2,0 µg/ml (26 %), 0,04 µg/ml (34 %) oziroma 8,9 µg.h/ml (21 %).
English: In vitro data tend to suggest that the continuation of lamivudine in anti-retroviral regimen despite the development of M184V might provide residual anti-retroviral activity (likely through impaired viral fitness).
Slovenian: Podatki, pridobljeni in vitro, nakazujejo, da se pri nadaljevanju uporabe lamivudina v režimu protiretrovirusnega zdravljenja kljub razvoju M184V lahko ohrani rezidualno protiretrovirusno delovanje (verjetno zaradi okvare virusa).
English: If you have taken Lamivudine Teva Pharma B.V. during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child.
Slovenian: jemali med nosečnostjo, vas lahko zdravnik naroči na redne preiskave krvi in druge diagnostične preiskave, da bo spremljal razvoj vašega otroka.
English: In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
Slovenian: Pri bolnikih, ki se sočasno protivirusno zdravijo zaradi hepatitisa B ali C, je treba upoštevati tudi ustrezne podatke o teh zdravilih.
English: Other possible side effects of combination therapy for HIV Combination therapy including Lamivudine Teva Pharma B.V. may cause other conditions to develop during HIV treatment.
Slovenian: Drugi možni neželeni učinki kombiniranega zdravljenja okužbe s HIV Kombinirano zdravljenje, ki vključuje zdravilo Lamivudine Teva Pharma B.V., lahko med zdravljenjem okužbe s HIV povzroči nastanek drugih motenj.
English: In PENTA 15 study, the geometric mean plasma lamivudine AUC(0-24) (95% CI) of the four subjects under 12 months of age who switch from a twice daily to a once daily regimen (see section 5.1) are 10.31 (6.26, 17.0) µg•h/mL in the once-daily dosing and 9.24 (4.66, 18.3) µg•h/mL in the twice-daily dosing.
Slovenian: V študiji PENTA 15 je bila geometrična srednja vrednost AUC(0-24) (95-% IZ) lamivudina v plazmi pri štirih preiskovancih, mlajših od 12 mesecev, ki so prešli z režima odmerjanja dvakrat na dan na režim odmerjanja enkrat na dan (glejte poglavje 5.1) 10,31 (6,26; 17,0) µg.h/ml med odmerjanjem enkrat na dan ter 9,24 (4,66; 18,3) µg.h/ml med odmerjanjem dvakrat na dan.
English: -4.8% (95% CI -11.5% to +1.9%), p=0.16 Week 48
Slovenian: -4,8 % (95-% IZ od -11,5 % do +1,9 %), p = 0,16
English: Therefore to achieve similar adult and paediatric exposure, an appropriate dose for neonates is 4 mg/kg/day.
Slovenian: Zato je primeren odmerek za novorojenčke, ki omogoča dosego podobne izpostavljenosti kot pri odraslih in pediatričnih bolnikih, 4 mg/kg/dan.
English: -1.6% (95% CI -8.4% to +5.2%), p=0.65 Week 96
Slovenian: -1,6 % (95-% IZ od -8,4 % do +5,2 %), p = 0,65
English: Based on data derived from a study in healthy volunteers, at a therapeutic dose of 150 mg twice daily, mean (CV) steady-state Cmax and Cmin of lamivudine in plasma are 1.2 µg/ml (24%) and 0.09 µg/ml (27%), respectively.
Slovenian: Na podlagi podatkov, pridobljenih v študiji z zdravimi prostovoljci, je pri terapevtskih odmerkih 150 mg dvakrat dnevno povprečna (KV) vrednost Cmax lamivudina v plazmi v stanju dinamičnega ravnovesja 1,2 µg/ml (24 %), vrednost Cmin pa 0,09 µg/ml (27 %).
English: In vitro studies indicate that zidovudine-resistant virus isolates can become zidovudine sensitive when they simultaneously acquire resistance to lamivudine.
Slovenian: Študije in vitro kažejo, da lahko virusni izolati, odporni na zidovudin, razvijejo občutljivost na zidovudin, če sočasno razvijejo odpornost na lamivudin.
English: Administration of lamivudine in animal toxicity studies at high doses was not associated with any major organ toxicity.
Slovenian: V študijah toksičnosti pri živalih dajanje velikih odmerkov lamivudina ni bilo povezano s toksičnostjo za kakšen pomemben organ.
English: Children from three months of age: As an accurate dosage cannot be achieved with the 300 mg nonscored tablet formulation in this patient population, it is recommended that the Lamivudine Teva Pharma B.V. 150 mg scored tablet formulation is used and the corresponding recommended dosage instructions are followed.
Slovenian: Otroci, starejši od treh mesecev: Ker pri tej populaciji bolnikov ne moremo zagotoviti točnega odmerka s 300 mg tableto brez razdelilne zareze, je priporočljiva uporaba zdravila Lamivudine Teva Pharma B.V.
English: Tablet film coat Hypromellose 3cP Hypromellose 6cP Titanium dioxide Macrogol 400
Slovenian: Filmska obloga tablete hipromeloza 3cP hipromeloza 6cP titanov dioksid makrogol 400 polisorbat 80 rumeni železov oksid črni železov oksid
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Slovenian: Opisan je bil tudi pojav avtoimunskih bolezni (npr. pojav Gravesove bolezni in avtoimunski hepatitis), toda opisani čas do začetka je bolj spremenljiv in ti učinki se lahko pojavijo veliko mesecev po uvedbi zdravljenja (glejte poglavje 4.4).
English: If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor about the risks and benefits to you and your baby of taking Lamivudine Teva Pharma B.V.. Lamivudine Teva Pharma B.V. and similar medicines may cause side effects in unborn babies.
Slovenian: Če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom o tveganjih in koristih jemanja zdravila Lamivudine Teva Pharma B.V.
English: Microcrystalline cellulose Sodium starch glycolate (Type A) Magnesium Stearate
Slovenian: Jedro tablete mikrokristalna celuloza natrijev karboksimetilškrob (vrste A) magnezijev stearat
English: Respiratory, thoracic and mediastinal disorders Common: Cough, nasal symptoms.
Slovenian: Bolezni dihal, prsnega koša in mediastinalnega prostora Pogosti: kašelj, nosni simptomi.
English: Administration of trimethoprim/sulfamethoxazole 160 mg/800 mg results in a 40% increase in lamivudine exposure, because of the trimethoprim component; the sulfamethoxazole component did not interact.
Slovenian: Po vnosu 160 mg trimetoprima/800 mg sulfametoksazola se izpostavljenost lamivudinu poveča za 40 %.
English: The dose should therefore be adjusted, using an oral solution presentation of lamivudine for patients whose creatinine clearance falls below 30 ml/min (see tables).
Slovenian: Zato je treba odmerek ustrezno prilagoditi, pri bolnikih, ki imajo kreatininski očistek manjši od 30 ml/min, z uvedbo peroralne raztopine lamivudina (glejte tabele).
English: The clinical relevance of such findings remains, however, not well defined.
Slovenian: Vendar pa klinična pomembnost teh odkritij še ni dobro raziskana.
English: Children receiving lamivudine oral tablets according to the recommended dosage regimen achieve higher plasma lamivudine exposure than children receiving oral solution because higher mg/kg doses are administered with the tablet formulation and the tablet formulation has higher bioavailability (see section 4.2).
Slovenian: Otroci, ki prejemajo lamivudin v obliki peroralnih tablet po priporočenem režimu odmerjanja, dosežejo višjo izpostavljenost lamivudinu v plazmi kot otroci, ki prejemajo peroralno raztopino; v obliki tablet se namreč dajejo večji odmerki v mg/kg, poleg tega pa imajo tablete večjo biološko uporabnost (glejte poglavje 4.2).
English: - The active substance is lamivudine.
Slovenian: - Učinkovina je lamivudin.
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Slovenian: V okviru imunske reaktivacije je bil opisan tudi pojav avtoimunskih bolezni (npr. pojav Gravesove bolezni in avtoimunski hepatitis), toda opisani čas do začetka je bolj spremenljiv in ti učinki se lahko pojavijo veliko mesecev po uvedbi zdravljenja.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/09/596/014
Slovenian: ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/09/596/014
English: Tablet film coat: Hypromellose, titanium dioxide (E171), macrogol, polysorbate 80, iron oxide yellow (E172), iron oxide black (E172)
Slovenian: jedro tablete: mikrokristalna celuloza, natrijev glikolat škroba, magnezijev stearat; filmska obloga tablete: hipromeloza, titanov dioksid (E171), makrogol, polisorbat 80, rumeni železov oksid (E172) in črni železov oksid (E172).
English: Lamivudine 4 mg/kg TwiceDaily Dosing Geometric Mean (95% Cl)
Slovenian: Lamivudin odmerjanje 4 mg/kg dvakrat na dan, geometrična sredina (95% IZ)
English: Talk to your doctor if any of these apply to you.
Slovenian: Posvetujte se z zdravnikom, če se kar koli od tega nanaša na vas.
English: Lamivudine demonstrates low cytotoxicity to peripheral blood lymphocytes, to established lymphocyte and monocyte-macrophage cell lines, and to a variety of bone marrow progenitor cells in vitro.
Slovenian: Lamivudin izkazuje in vitro majhno citotoksičnost do limfocitov v perifernem krvnem obtoku, do dozorelih limfocitov, celičnih linij monocitov-makrofagov in vrste progenitorskih celic kostnega mozga.
English: Children weighing 14 kg to <20 kg: The recommended dose is 150 mg daily.
Slovenian: Otroci, ki tehtajo med 14 in < 20 kg: Priporočeni odmerek je 150 mg dnevno.
English: Common: Nausea, vomiting, abdominal pain or cramps, diarrhoea.
Slovenian: Pogosti: navzeja, bruhanje, bolečine ali krči v trebuhu, diareja.